FIGURE 5.

Bevacizumab and L1-10 treatment reduces metastatic burden in brain. Representative images of MDA-MB-231-BR-Her2 non-treated metastatic brain (A), bevacizumab treated brain (B), and bevacizumab + L1-10 treated brain (C). Bevacizumab (10 mg/kg) or bevacizumab + L1-10 (4 mg/kg) was administered on day 10 after inoculation (with cancer cells and the number of metastatic lesions developed was significantly (p < 0.001) reduced in the bevacizumab alone group (56%) and in the combination group (86%) (D). Treatment also reduced lesion size with 67% ± 1 of bevacizumab treated lesions and 78% ± 10 of bevacizumab + L1-10 treated lesions developing area < 0.5 mm². Data illustrate a significant reduction in metastatic burden with simultaneous inhibition of the VEGF/angiopoietin-2 pathway. Significance was determined using ANOVA analysis followed by Bonferroni’s multiple comparisons test; ^∗ for p < 0.05, ^∗∗ for p < 0.01 and ^∗∗∗ for p < 0.001.)